Exeter Chiefs have secured a Premiership Women’s Rugby (PWR) semi-final showdown against Saracens on 13 June, driven by a dominant performance from England international Claudia Moloney-MacDonald. Moloney-MacDonald scored four tries in Exeter’s 50-24 victory over Sale, bringing her season tally to 14 scores and cementing the club’s momentum heading into the playoffs.
How Exeter Chiefs Built Playoff Momentum
Exeter’s path to the semi-finals was confirmed at a windy Sandy Park, where they played before a season-high crowd of 2,543 fans. According to match reports, the hosts overcame a bright start from Sale to secure a 24-12 half-time lead. The victory was punctuated by milestone moments, including scrum-half Flo Robinson becoming only the fourth women’s player to reach 100 appearances for the club.
The 30-year-old Moloney-MacDonald, who previously scored two tries against Bristol, credited the squad’s collective focus for the result. “We went out there today to try and put out a performance to build momentum into a semi-final and that is exactly what we did,” she said. Exeter will now travel to StoneX Stadium to face a Saracens side that finished their regular season with a resounding 80-14 win over Ealing Trailfinders.
Exeter’s semi-final opponent, Saracens, maintained a solid second-place position throughout the regular season, while the other semi-final will feature three-time defending champions Gloucester-Hartpury against Ealing Trailfinders.
Why the Premiership Women’s Rugby Landscape is Shifting
The league is seeing significant personnel movement as clubs prepare for the next campaign. Sale, despite finishing this season with their best league table result since 2022/23, is already restructuring its squad. The northern club has confirmed the signings of England internationals Zoe Stratford, Tatyana Heard, and Sarah Beckett from Gloucester for next season.
The competitive balance remains fluid. While Gloucester-Hartpury finished at the top of the table, Ealing Trailfinders recently demonstrated that the hierarchy can be challenged, having ended Gloucester’s unbeaten run that stretched back to November 2024. Meanwhile, the search for talent continues; England’s Ellie Kildunne remains a high-profile free agent following her departure from Harlequins, with her next destination yet to be confirmed.
Frequently Asked Questions
Who will Exeter Chiefs play in the PWR semi-final?
Exeter will face Saracens at the StoneX Stadium on 13 June.
How many tries did Claudia Moloney-MacDonald score against Sale?
Moloney-MacDonald scored four tries in the 50-24 victory, taking her total for the current season to 14.
Which teams are competing in the other semi-final?
The second semi-final features Gloucester-Hartpury and Ealing Trailfinders.
Are you following the Premiership Women’s Rugby playoffs? Share your predictions for the final in the comments below, or subscribe to our newsletter for weekly updates on the latest player transfers and match results.
Related reading
- Serie A Title Race & De Zerbi: Italy’s Tactical Confusion Explained
- Swedish Players and Captains Lead Europe to Solheim Cup Victory
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)